Full Fed. Circ. Urged To Review 'Unclear' Double-Patent Rules

Law360 (January 8, 2019, 7:31 PM EST) -- Generics maker Hikma asked the full Federal Circuit Monday to rehear a decision that a Novartis cancer drug patent is not invalid for double-patenting, saying the ruling conflicts with precedent and leaves what had been a straightforward standard “fragmented and unclear.”

Hikma Pharmaceuticals International Ltd. said in its petition for en banc rehearing that the appeals court had previously held that the date patents expire is the key to determining invalidity based on double-patenting, but that the December decision shifted the focus onto when the patents issued.

Double-patenting, which prevents companies from obtaining patents that are so similar that granting both...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!